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This study is about proteomic analysis of oral verrucous carcinoma (OVC). The total proteins obtained 
from tumour and adjacent normal oral mucosa of patients with OVC and oral squamous cell carcinoma 
(OSCC) were separated with two dimensional electrophoresis (2-DE) by using immobilized pH gradient 
strips and visualized by staining with silver nitrate. The gel images were acquired by scanner and 2-DE 
analysed by image master 2D elite. Twenty distinct protein spots were excised from gel randomly and 
digested in gel by TPCK-trypsin. Mass analysis of the tryptic digested peptides mixture was performed 
by using MALDI-TOF-MS. Peptide mass fingerprints (PMFs) obtained by the MALDI-TOF analysis were 
applied to National Center for Biotechnology Information (NCBI), SWISS-PROT and MSDB databases 
using Mascot software. Then the 2-DE gel imaging showed that 74, 36 and 31 differential protein spots 
were found between OVC and OSCC, OVC and adjacent normal oral mucosa of OVC (OVCN), OSCC and 
adjacent normal oral mucosa of OSCC (OSCCN) samples, respectively. By identification of protein spots 
from 2-DE gels, 20 PMF maps were obtained by MALDI-TOF-MS including recoverin (cancer associated 
retinopathy (CAR) protein) tumor protein D53 (hD53), zinc finger protein 77 (ZNFpT1) and so on and 
these protein may play a key role in the carcinogenesis of OVC and OSCC. 
  
Key words: Oral verrucous carcinoma, oral squamous cell carcinoma, two-dimensional electrophoresis, 
peptide mass fingerprints, matrix-assisted laser desorption/ionization-time of flight mass spectrometry. 
 
 
INTRODUCTION    
 
Oral verrucous carcinoma (OVC) is a rare variant of oral 
squamous cell carcinoma (OSCC) with a characteristic 
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frequently in the oral cavity and larynx (Koch et al., 2001; 
McCoy and Waldron, 1981), representing anywhere from 
1 to 10% of all oral squamous malignancies (Bouquot, 
1998). The common sites of involvement in the mouth are 
the buccal mucosa and the gingiva, the alveolar ridge, 
the palate and the tongue. Comparing with conventional 
squamous cell carcinomas of the head and neck, they 
tend to present at an advanced age, with a higher 
proportion of male patients. It is a slow growing, low-
grade, well-differentiated tumor that presents clinically as 
an exophytic, verrucoid papule or plaque on the skin or 
mucosa (Batsakis et al., 1982). Lymph node and distant 
metastases are rare during any stage of this tumor 
(McCoy and Waldron, 1981; Batsakis et al., 1982). 





their local invasiveness and their pattern of stubborn 
recurrence with the currently acceptable modalities of 
radiation, surgery and intraarterial chemotherapy (Elliott 
et al., 1973; Krishnan et al., 1988; Wu et al., 2008). 
In contrast to the traditional concepts, OVC is recently 
classified into three kinds of clinical phenotypes including 
exogenic type, infiltrative type and cystoid type. Lymph 
node and implant metastasis can be found in infiltrative 
type and cystoid type (Schrader et al., 1987; Tang et al., 
2005). The mechanisms behind OVC’s phenotypes 
remain unknown.  
The study is able to identify the entire protein com-
ponents' changes in the tissues which can provide insight 
into the mechanisms of the diseases and can help to 
discover biomarkers for diagnosis and guide clinic 
therapeutics (Banks et al., 2000; Graves and Haystead, 
2002). In the present work, we applied proteomic analysis 




MATERIALS AND METHODS 
 
Patients and tissue sampling 
 
Frozen samples from four patients with OVC and four patients with 
OSCC were obtained from Central South University Xiangya 
Hospital (Changsha, China). The pairs of underwent surgical 
specimens from both tumour and adjacent normal mucosa were 
collected. The age of the patients of OVC at the time of diagnosis 
are 38\35\53\46 (all are males) with a mean of 43 years, and OSCC 
are 63\53\68\60 (one female and the other are males) with a mean 
of 61 years. According to the criteria from the American Joint 
Committee on Cancer for pathological stages, there were 4 of T3N0 
and 4 of T2N0. The stage of the cancer was defined by the extent 
of the lesion and was determined by physical examination, 
radiological studies and morphological examination. The 
histological diagnosis was made by two independent histo-
pathologists. No tumor cells were detected in the surrounding 
mucosal tissues by histological examination. The study was 
approved by the ethical committee of Human Ethics Committee of 
Hunan Province, China. 
 
 
Chemicals and materials 
 
Tetramethylethylethylendeiame (TEMED) and acetonitrile were 
purchased from Sigma (St Louis, MO, USA). Urea, sodium dodecyl 
sulphate (SDS), glycine, Tris, bromophenol blue, ammonium 
persuphate, trypsin (sequencing grade), a-cyano-4-hydro-
xycinnamic acid (a-HCCA), trifluoroacetic acid (TFA), dithiothreitol 
(DTT), acrylamide, methylenebisacrylamide, CHAPS, thiourea and 
iodoacetamide were purchased from Shanghai Biocompany. 
PhastGel Blue tablets, immobiline pH-gradient (IPG) strip (pH 3 to 
10), pharmalyte (pH 3 to 10), IPG buffer (pH 3 to 10) were obtained 





All tissues were rinsed using phosphate buffered saline (PBS) and 
minced into pieces of about 1 to 2 mm
3
 and then homogenized with 
0.5 ml lysis buffer (8 mol/l urea, 4% CHAPS), containing protease 
inhibitor  cocktail,  by  a   homogenizer  for  60 s  at  6500 rpm.  The  




lysates were centrifuged at 8000 rpm for 20 min at 4°C and 
supernatants were collected for acetone precipitation for protein 
purification. The protein pellet was denatured with sample buffer (8 
mol/l urea, 4% CHAPS, 65 mmol/l 1, 4-dithioerythritol (DTE), 0.5% 
ampholytes). The denatured proteins were incubated at 4°C 2 to 3 h 
before centrifugation at 13,000 rpm for 15 min. The protein 
concentrations of the resulting supernatants were measured.  
 
 
Two-dimensional difference gel electrophoresis  
 
600 µg protein extractions per sample were taken for two 
dimensional (2D) gel separation. The extracted samples were 
diluted to 450 µl with rehydration buffer consisting of an 8 mol/l 
urea, 4% CHAPS, 65 mmol/l DTE, 0.5% ampholytes and traced by 
bromophenol blue. The rehydration solution was applied into 
immobilized pH gradient pH 3 to 10 IPG strip (240 mm× 3 mm× 0.5 
mm) overnight. Electrophoresis in the first dimension was focused 
for a total of 64980 V h at 20°C and then was as following 20°C 30 
V for 16 h (rehydration), 500 V for 1 h, grad 1000 V for 1 h, grad 
3500 V for 2 h and 8000 V for 7.5 h. After isoelectric focusing (IEF), 
the strips were first equilibrated in equilibration solution of 50 mM 
Tris-HCl (pH 8.8), 6 M urea, 30% (V/V) glycerol, 2% (W/V) SDS and 
1% (W/V) DTT for 15 min and later in the same solution except that 
DTT was replaced by 4% (W/V) iodoacetamide for another 15 min. 
Finally, the strip was transferred to the top of 12% polyacrylamide 
gels and held in position with molten 0.5% agarose in running buffer 
containing 25 mmol/l Tris, 0.192 mol/l glycine and 0.1% SDS. Gels 
were run at 20 mA/2 gels for 20 min followed by 40 mA/2 gel for 4 
to 6 h. 
 
 
Image and statistic analysis 
 
Gels were routinely stained with silver nitrate and then scanned by 
300 DPI imaging densitometer with image master 2D Elite software. 
Protein spots were quantified using the image master 2D elite 
software. To compare the tumor with normal samples from 8 
patients, we screened the over-expressed proteins (≥5-fold) in 
tumor samples for the advance analysis. Comparisons were made 
between gel images of individual tumor and normal samples by 
image master 2D elite software. The pixel volume of each spot was 
calculated, normalized and compared between the two groups with 
t-test. Every gel was normalized with its internal standard image. 
Normalized volume differences were statistically calculated. 
Consistently and significantly over-expressed spots (≥5-fold) were 
averaged in each protein and selected for analysis. 
 
 
Protein identification  
 
Gel plugs picked were digested with trypsin automatically on Ettan 
Digester. First they were destained with 50 mM NH4HCO3 and 50% 
methanol and then dehydrated with 50% acetonitrile (ACN) and 
0.1% trifluoroacetic acid (TFA). After the gel plugs were completely 
dried, trypsin solution (20 ng/ll in 20 mM ammonium bicarbonate) 
was added and the samples were digested at room temperature 
overnight. The extracted peptides were removed, dried and re-
suspended in 50% ACN-0.1% TFA. Equal volume of sample and a-
HCCA were spotted and mixed on the MALDI-TOF target slides by 
Ettan spotter (Millipore, USA). Peptide extracts were analyzed on a 
MALDI-TOF-MS (BRUKERGS, USA) in positive ion reflectron 
mode. The accelerating potential was 20 KV with eight-shots per 
second. Trypsin auto digestion peaks were used as internal 
calibration and hACTH (19-39) and Ang III as external. Peptide 
mass data were searched against National Center for 
Biotechnology Information (NCBI) with the search engine of 
profound with homo sapiens as  the  species  searched.  The  basic  




requirement for identification was that the expectation value is 
<0.05 (<5% chance of error) and the coverage is >20%. The results 






Proteomic patterns of OVC and OSCC by 2-DE  
 
Proteins obtained from tumour and adjacent normal tis-
sues were separated by 2-DE. Spots were visualized with 
silver staining (Figures 1 and 2). Three pairs of gels from 
OVC and OSCC were analyzed using the image master 
2D elite software. Nearly 1200 proteins spots were 
obtained in the range of Mr 14,400-9 4000 u, PI 3-10. 
  Averages of 1186 spots of OVC and 1076 spots of 
OSCC were detected across all gels. Fully automated 
spot detection and quantification were performed for 
paired samples by image master 2D elite software. The 
ratio values were compared and abundance ratios 
between different samples from different gels were 
calculated. The ratio values were expressed as fold 
changes. And a 5-fold increase in tumors was expressed 
as 5.0. In the OVC tissues, 36 commonly differential 
protein spots were found by comparing with the paired 
normal tissue. There were only 10 protein spots that 
consistently showed significant over-expression in all 
OVC tissues. Statistical analysis is summarized in Table 
1, to indicate fold differences in OVC tissues, against the 
normal tissue pairs. Among the 10 over-expressed 
proteins, D53 was the lowest (5.13-fold). In the OSCC 
tissues, 31 commonly differential protein spots were 
found by comparing with the normal tissue pairs. There 
were 10 protein spots that consistently showed significant 
over-expression in all OSCC tissues. Statistical analysis 
were summarized in Table 2, to indicate fold differences 
in OSCC tissues, details and statistical analysis were 
summarized in Table 2. 
 
 
Protein identification by MALDI-TOF MS analysis  
 
Ten distinct protein spots were excised from gels 
randomly and marked with numbers at the corresponding 
sites in Figures 1 and 2. All spots obtained the PMF maps 
by MALDI-TOF MS following in-gel digestion with TPCK-
trypsin. Figures 3 and 4 showed the spectrum of trypsin 
digestion of protein spot 6 in tumour tissue and protein 
spot 3 in the matching normal tissue. The results are 
summarized in Tables 3 and 4. Among those 10 over-
expressed proteins, most of the matched proteins had 
high sequence coverage, accession number, theoretical 










common cancer of the head and neck and accounts for 
over 300 000 new cancer cases worldwide annually 
(Lippman et al., 2005). Oral cancer remains one of the 
leading causes of death among human. As a rare variant 
of SCC, oral verrucous carcinoma (OVC) has a frequency 
of 0.3 to 10% occurred within the oral cavity (Bouquot, 
1998; Kouzu et al., 2006). Recently, new protein markers 
have to be identified for its early detection and it is 
important in cancer early diagnosis and treatment. Using 
the 2-DE technology, picking out single spots, tryptic 
digestion and sequencing by MS to identify new potential 
biomarkers by proteomics is also a current and effective 
technology. The protein spots of interest could be been 
used to identify potential biomarkers for the disease. Our 
previous studies have indicated that, OVC has three 
kinds of clinical phenotypes and has a difference in 
genotypes compared with its matching normal tissue 
(Tang et al., 2007). To further understand the cellular 
function of OVC, we performed proteomics analysis to 
investigate the level of specific proteins related to OVC.  
Ten of the total 1186 proteins with over 5.0-fold 
induction were consistently identified within 4 OVC cases 
by this proteomic analysis (Table 1). They may play a role 
in the malignant alteration of oral mucosal epithelial cells.      
Cancer associated retinopathy (CAR) is paraneoplastic 
syndrome of ocular manifestation of paraneoplastic 
syndrome and is clinically characterized by progressive 
visual impairment which is similar to retinitis pigmentosa. 
The pathogenesis of CAR is assumed to be the result of 
retinal cell apoptosis with the expression of a photo-
receptor protein (recoverin) through autoimmunity 
(Shiraga and Adams 2002). Recoverin is a calcium-
binding protein that is expressed in retinal photore-
ceptors. It appears to delay the termination of the 
phototransduction cascade by blocking the phosphor-
rylation of photoexcited rhodopsin. Recoverin is 
expressed in one novel small cell lung carcinoma cell line 
(SCLC, KK0206), which is derived from a relapsed SCLC 
patient with CAR but without recoverin expression. The 
reason is that CAR patient with negative recoverin 
expression is unknown (Makoto et al., 2007). In our study, 
there is 22 fold difference for recoverin expression 
between OVC and its matching tissue, the function of 
recoverin in OVC development may need to be further-
more investigated in future. 
The zinc finger gene (ZNF) family plays an important 
role in the regulation of transcription (Tarik et al., 2008). 
Members of this family are exclusively fungal and 
possess the well-conserved motif CysX2CysX6CysX5-
12CysX2CysX6-8Cys (Sarah et al., 2006).The cysteine 
residues bind to two zinc atoms, which coordinate folding 
of the domain involved in DNA recognition. Since the 
discovery of Gal4p, many other zinc cluster proteins have 
been characterized; their function was in a wide range of 
processes, including primary and secondary metabolism 
and meiosis. Other roles include regulation of genes 
involved in the stress response as well as pleiotropic drug  






Figure 1.  2-DE map of human oral verrucous carcinoma tissue and the normal tissue pair 
extracts Six hundred micrograms of proteins were separated on 24 cm gels followed by silver 
staining. (A) Protein expression profiles of tumour tissue from one OVC patients; (B) the profiles 
of matched adjacent normal tissues from the same patients (the numbers means the commonly 
differential protein spots). 






Figure 2. 2-DE map of human Oral squamous cell carcinoma tissue and the normal tissue pair 
extracts. Six hundred micrograms of proteins were separated on 24 cm gels followed by silver 
staining. (A) Protein expression profiles of tumour tissue from one OSCC patients; (B) the profiles 
of matched adjacent normal tissues from the same patients.  














V1 Tumor protein D53 70656±293 13773±326 5.13 
V2 Recoverin (CAR protein) 92812±269 4161±103 22.30 
V3 Ras-related protein Rap-2a 52820±373 7871±156 6.71 
V4 S-phase kinase-associated protein 1A 22841±432 2367±97 9.65 
V5 DNA repair protein RAD51 homolog 4 49139±398 5992±163 8.20 
V6 Ras-related protein Rab-3B 32782±261 4629±172 7.08 
V7 Zinc finger protein 77 40220±308 3901±125 10.31 
N1 Isoform of Nuclear receptor ROR-
alpha 
7502±141 49439±157 6.59 
N2 Modulator recognition factor protein 2 6956±291 55928±263 8.04 




Table 2. Ten over-expressed proteins in OSCC tissues comparing with adjacent normal tissues. 
 







T1 Phospholipase A2 inhibitory protein 51468±652 8889±348 5.79 
T2 Melanoma antigen recognized by T-cells 1(MART-1) 38879±421 4438±291 8.76 
T3 Isoform of DNA-binding protein Ikaros 48283±186 7568±237 6.38 
T4 CHAIN 1: Endothelial cell-specific molecule 1 18397±339 3426±265 5.37 
T5 Isoform of caspase-6 precursor (EC 3.4.22) 22906±145 4527±210 5.06 
T6 CHAIN 2:Complement factor I heavy chain 64583±384 8704±163 7.42 
T7 Eukaryotic translation initiation factor 2 subunit 
2(Eukaryotic translation initiation factor 2 beta subunit) 
24346±525 4517±265 5.39 
N1 Calbindin (Vitamin D-dependent calcium-binding protein, 
avian-type) 
12975±360 76814±605 5.92 
N2 Zinc-finger protein ubi-d4(Requiem) (Apoptosis response 
zinc finger protein) 
13495±293 85562±347 6.34 
N3 Isoform of Nuclear receptor ROR-alpha (Nuclear receptor 
RZR-alpha) 




resistance, as demonstrated in budding yeast and in 
human fungal pathogens. With the number of charac-
terized zinc cluster proteins growing rapidly, it is be-
coming more and more important (Li et al., 2008; Li et al.,  
2007; Huang et al., 2007). 
The putative adaptor protein D53, a member of the 
D52-like family, works as a novel 14-3-3 binding partner 
in breast cancer cells9 (Boutros et al., 2003). Recently, 
studies show that cytoplasmic protein whose capacity to 
bind 14-3-3 is regulated by the alternative splicing of an 
exon encoding a canonical 14-3-3 binding motif (Boutros 
et al., 2003). D52-like proteins were first identified for 
their expression in breast cancer (Mona et al., 2008; 
Wang et al., 2004; Nourse et al., 1998) and confirmed 
with numerous studies for D52 upregulation in human 
breast (Balleine et al., 2000; Pollack et al., 2002; Ross 
and Perou, 2001) and other (Cao et al., 2006; Rhodes et 
al., 2002) cancers. Recent microarray studies have 
identified D53 as a gene whose transcript abundance 
significantly varies according to cell cycle stage in 
primary human fibroblasts (Cho et al., 2001) and HeLa 
cells (Whitfield et al., 2002; Wichert et al., 2004) or 
according to circadian rhythms in mouse liver (Wei et al., 
2006). In the latter study, D53 was reported to form part 
of gene cluster implicated in cell division, cell death and 
chromosome segregation (Akhtar et al., 2002). This study 
found that, D53 was highly over expressed in tumour 
than its matched normal indicating that it may be used as 
a differentiation marker.  
In conclusion, we identified 10 proteins just as 
recoverin (cancer associated retinopathy protein), (CAR 
protein) tumor protein D53 (hD53), zinc finger protein 77 
(ZNFpT1) may be involved in the pathogenesis of OVC 
and  they  may  be   used   as  potential  markers  for  the  






Figure 3. PMF of protein spot 3 and spot 6 in OVC 2-DE map (N3 upper and V6 down).  
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AC Description pI Mass 
weight 
Coverage% 
V1 4/21 Q16890 Tumor protein D53 (hD53) (D52-like 1). - Homo 
sapiens (Human). 
5.45 22449.07 24.5 
V2 4/26 P35243 Recoverin (Cancer associated retinopathy protein) 
(CAR protein). - Homo sapiens (Human).. 
5.06 22999.07 31.7 
V3 4/25 P10114 
 
Ras-related protein Rap-2a. - Homo sapiens 
(Human). 
4.73 20615.46 31.1 
V4 6/32 P34991 S-phase kinase-associated protein 1A (Cyclin 
A/CDK2-associated protein p19) (p19A) (p19skp1) 
(RNA polymerase II elongation factor-like protein). 
4.40 18526.81 22.2 
V5 5/33 075771 
 
DNA repair protein RAD51 homolog 4 (R51H3) 
(TRAD). - Homo sapiens (Human). 
5.89 35049.32 18.0 
V6 4/22 P20337 Ras-related protein Rab-3B. - Homo sapiens 
(Human). 
4.85 24757.90 19.6 
V7 5/17 Q15935 Zinc finger protein 77 (ZNFpT1) (Fragment). - 




N1 4/13 Q96E17 Isoform of Nuclear receptor ROR-alpha (Nuclear 
receptor RZR-alpha) - Homo sapiens (Human). 
5.09 25952.19 16.3 
N2 4/29 Q14865 Modulator recognition factor protein 2 (Mrf-2)  - 




N3 5/26 P04070 
 
CHAIN 2: Vitamin K-dependent protein C light - 
Homo sapiens (Human). 













T1 19/29 P04083 Phospholipase A2 inhibitory protein 6.54 38583.05 64.3 
T2 4/17 Q16655 Melanoma antigen recognized by T-cells 1(MART-1) 
(Melan-A protein) (Antigen SK29-AA) (Antigen LB39-
AA) Homo sapiens (Human). 
5.29 23157.03 22.9 
T3 6/22 Q13422 
(Isoform) 
Isoform of DNA-binding protein Ikaros (Lymphoid 
transcription factor LyF-1).- Homo sapiens(Human). 
5.75 47633.96 18.7  
T4 7/22 Q9NQ30 CHAIN 1: Endothelial cell-specific molecule 1.- Homo 
sapiens(Human). 
5.83 28122.42 50.3 
T5 4/23 P55212 
(Isoform) 
Isoform of Caspase-6 precursor (EC 3.4.22.-) 
(Apoptotic protease Mch-2).- Homo sapiens (Human). 
6.69 22573.80 21.5 
T6 6/25 P05156 CHAIN 2: Complement factor i heavy chain - Homo 
sapiens (Human). 
5.69 25286.22 24.9 
T7 4/19 P20042 Eukaryotic translation initiation factor 2 subunit 
2(Eukaryotic translation initiation factor 2 beta subunit) 
(elF-2-beta) - Homo sapiens (Human). 
5.60 28388.41 15.0 
N1 5/25 P05937 Calbindin (Vitamin D-dependent calcium-binding 
protein, avian-type) (CalbindinD28) (D-28K) - Homo 
sapiens (Human). 
4.70 29893.91 25.4 
N2 5/20 Q92785 Zinc-finger protein ubi-d4 (Requiem) (Apoptosis 
response zinc finger protein) - Homo sapiens 
(Human). 
5.94 44155.48 18.4 
N3 7/25 P35398 
(Isoform) 
Isoform of Nuclear receptor ROR-alpha (Nuclear 
receptor RZR-alpha) - Homo sapiens (Human). 
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